ORMP News and Press, Oramed Pharmaceuticals Inc. From 01/05/22

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins - Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system - Oramed has already been granted this patent in the United...

Oramed Pharmaceuticals' (NASDAQ:ORMP) subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax's oral COVID-19 vaccine, currently in development. The agreement grants Tan Thanh Holdi...

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia Initial pre-purchase of 10 million doses of oral vaccines with a potenti...

Oramed is a leading developer of an oral formulation of human insulin. It uses a permeability enhancer to enable intestinal absorption. A recent cash raise caused the stock to fall drastically. For further details see: Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa Oravax's oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax's oral vaccine should of...

Oramed Pharmaceuticals Appoints Chief Legal Officer PR Newswire NEW YORK , Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral...

Oramed to Join MSCI USA Small Cap Index PR Newswire NEW YORK , Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery p...

Ocuphire Pharma (NASDAQ:OCUP) +74%. Biofrontera (NASDAQ:BFRI) +53%. Engine Gaming and Media (NASDAQ:GAME) +30% on FY results Longeveron (NASDAQ:LGVN) +16%. Inspira Technologies Oxy (NASDAQ:IINN) +15%. Society Pass Incorporated  (NASDAQ:SOPA) +15% on no apparent news Spark Netwo...

Oramed Pharmaceuticals (NASDAQ:ORMP) has enrolled and randomized over 75% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). Shares down 3.4% premarket at $18.30. ORA-D-013-1 is the larger o...

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study PR Newswire NEW YORK , Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of ...